Leiomyosarcoma Clinical Trials

15 studies are recruiting for leiomyosarcoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

   This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic Hospital in Arizona, Phoenix, Arizona

   Locations

   175 in total

   Run by

   European Organisation for Research and Treatment of Cancer - EORTC

   See if you can join NCT04031677 on ClinicalTrials.gov

2. A Study of Ivonescimab in People With Leiomyosarcoma

   The purpose of this study is to find out if Ivonescimab is an effective and safe treatment that causes few or mild side effects for people with advanced/unresectable leiomyosarcoma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07516925 on ClinicalTrials.gov

3. STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

   This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 [PD-1]) in advanced unresectable or metastatic tumors. The Phase 2…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   10 in total

   Run by

   STORM Therapeutics LTD

   See if you can join NCT06975293 on ClinicalTrials.gov

4. NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

   The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk * To estimate the 3-year event-free survival for intermediate-risk patients treated with ifosfamide, doxorubicin, pazopanib, surgery, and maintenance pazopanib, with or without RT. * To …

   Stage

   Phase 1

   Ages

   Up to 30

   Site

   Children's Healthcare of Atlanta, Atlanta, Georgia

   Locations

   7 in total

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT06239272 on ClinicalTrials.gov

5. Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

   This is a pilot clinical trial determining the effect of a Methionine-reduced diet on serum levels in subjects with solid tumors. These are subjects who will receive systemic standard of care cancer therapy.

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

   Run by

   University of California, Irvine

   See if you can join NCT07628634 on ClinicalTrials.gov

6. A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy

   To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT07633756 on ClinicalTrials.gov

7. Localized Leiomyosarcoma Biomarker Protocol

   * Leiomyosarcoma (LMS) is one of the more common soft tissue sarcomas (STS). * Patients presenting with large, high-grade, localized LMS are at significant risk of developing metastasis following curative surgery. * Clinical trials of neoadjuvant or adjuvant anthracycline and ifosfamide have sugges…

   Stage

   Not phased

   Ages

   Any age

   Site

   University of Michigan, Ann Arbor, Michigan

   Locations

   3 in total

   Run by

   University of Michigan Rogel Cancer Center

   See if you can join NCT04925089 on ClinicalTrials.gov

8. Metastatic Leiomyosarcoma Biomarker Protocol

   Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can occur in various sites including soft tissue, uterus and retroperitoneal large vessels. Metastatic disease occurs in approximately 50% of patients diagnosed with leiomyosarcoma and prognosis is poor in setting of m…

   Stage

   Not phased

   Ages

   Any age

   Site

   Sarcoma Oncology Research Center, Santa Monica, California

   Locations

   11 in total

   Run by

   University of Michigan Rogel Cancer Center

   See if you can join NCT05653388 on ClinicalTrials.gov

9. A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

   The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combinat…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Precision NextGen Oncology and Research Center, Beverly Hills, California

   Locations

   10 in total

   Run by

   Epkin

   See if you can join NCT06789172 on ClinicalTrials.gov

10. Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

    THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA. This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advanced alveolar soft pa…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Sarcoma Oncology Center, Santa Monica, California

    Locations

    24 in total

    Run by

    Advenchen Laboratories, LLC

    See if you can join NCT03016819 on ClinicalTrials.gov

11. A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

    To find a recommended dose of gemcitabine and nab-sirolimus that can be given in combination to participants with advanced leiomyosarcomas or soft-tissue sarcomas.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06308419 on ClinicalTrials.gov

12. Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

    A phase 2 study assessing the efficacy of all-trans retinoic acid (ATRA) and Cemiplimab in patients with metastatic/locally advanced - unresectable leiomyosarcoma (LMS) who have progressed standard-of-care therapy. Patients will be enrolled in cohorts according to a Bayesian Optimal Phase II design…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Run by

    Gabriel Tinoco

    See if you can join NCT06528769 on ClinicalTrials.gov

13. Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients

    Genomic research has shown that a portion of leiomyosarcomas can be attributed to an underlying cancer predisposition syndrome. However, the optimal approach for incorporating germline testing into the care of these patients. This study is assessing the beliefs about the heritability of leiomyosarc…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah

    Run by

    University of Utah

    See if you can join NCT06875700 on ClinicalTrials.gov

14. Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

    CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help …

    Stage

    Not phased

    Ages

    Any age

    Site

    Sanford Health, Sioux Falls, South Dakota

    Locations

    2 in total

    Run by

    Sanford Health

    See if you can join NCT01793168 on ClinicalTrials.gov

15. Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma

    This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Sant P Chawla, Santa Monica, California

    Run by

    Sarcoma Oncology Research Center, LLC

    See if you can join NCT04535271 on ClinicalTrials.gov